Summary: At its Investor Day on October 1, Harmony Biosciences presented a pipeline update, highlighting progress in its sleep disorder treatments. New data from the orexin-2 agonist BP1.15205 showed potential best-in-class potency, while long-term extension data for pitolisant … [Read more...]
Orexin-2 Receptor Agonist E2086 to Be Tested for Narcolepsy
Summary: Eisai Inc announced the registration and upcoming enrollment for Study E2086-A001-101, a clinical trial to evaluate the efficacy, safety, and tolerability of E2086, a novel selective orexin-2 receptor agonist, in adult patients with narcolepsy type 1. The trial, which … [Read more...]
Orexin-2 Receptor Agonist for Narcolepsy Enters Phase 2 Trials
Summary: Alkermes plc has launched the Vibrance-1 examine, a stage 2 medical trial to evaluate the basic safety and efficacy of ALKS 2680, a novel orexin-2 receptor agonist, in treating narcolepsy type 1. This oral treatment method aims to boost wakefulness by focusing on the … [Read more...]
Harmony Secures Rights to Develop Bioprojet’s Orexin-2 Agonist
Summary: Harmony Biosciences has secured an unique license from Bioprojet to establish, manufacture, and commercialize TPM-1116, an oral orexin-2 receptor agonist, in the United States and Latin The united states. This drug, aimed at dealing with narcolepsy and other rest … [Read more...]
NLS Secures Exclusive License for Dual Orexin Agonist Platform
Swiss biopharmaceutical enterprise NLS Pharmaceutics Ltd declared an exclusive worldwide license arrangement with Aexon Labs Inc, a US-centered biotech agency, to purchase global advancement and commercialization legal rights to Aexon’s twin orexin receptor agonists system. These … [Read more...]